Guru P. Sonpavde MD
Genitourinary Oncology Director, Christopher K. Glanz Chair for Bladder Cancer Research, Assistant Director Phase I Clinical Research Unit, AdventHealth Cancer Institute, Orlando, FloridaDr. Guru Sonpavde, MD, is the Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research. He completed his fellowship in medical oncology and hematology at Indiana University. He leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.
Disclosures
Dr. Sonpavde reports the following:
-
Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV
-
Research Support: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric, Kure it, NCI (R21)
- Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid)
- Data safety monitoring committee: Mereo
- Employment: Spouse employed by Myriad
- Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence
- Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)
Recent Contributions to PracticeUpdate:
- ASCO GU 2024: Bladder Cancer Highlights
- 2023 Top Story in Oncology: EV-302 and CheckMate 901 Will Dramatically Alter First-Line Therapy for Metastatic Urothelial Carcinoma
- Nivolumab Plus Gemcitabine–Cisplatin for Advanced Urothelial Carcinoma
- Two Trials in Metastatic Urothelial Carcinoma: Phase I DAD and Phase III THOR
- EV-302 and CheckMate 901: Wins in Bladder Cancer
- ESMO 2023: Recommendations From Dr. Guru Sonpavde for Bladder Cancer
- ASCO 2023: Abstract Recommendations From Dr. Guru Sonpavde for Bladder Cancer
- 2022 Top Story in Bladder Cancer: Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
- Any Regression of Tumor (ART) as a Potential Intermediate Endpoint in Patients With Solid Tumors Receiving ICIs
- Searching Out Baseline Variables Associated With Response to PD-L1 Inhibition in Patients With Metastatic Urothelial Carcinoma Progressing After Chemotherapy